Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
88 Cards in this Set
- Front
- Back
What are the key steps in vascular repair following vessel wall injury? |
Platelet activation and aggregation |
|
When doest Platelet Activation occur? |
Rupture of atheromatous plaque exposes circulating platelets to: ADP, TxA2, epinephrine, thrombin, Collagen tissue factor |
|
What is the potent stimulant for platelet activation? |
Thrombin |
|
When does Platelet aggregation occur? |
1) Platelet activation leads to expression of GP on platelet surface. 2) GP receptors lead to binding of fibrinogen between adjacent platelets 3) Leads to platelet aggregation |
|
What is the VW factor? |
protein found on the vessel wall and plasma |
|
Process of activation and aggregation are ______ |
Progressive and overlapping event 1) Platelets changes shape 2) Develop pseudopods |
|
A central element in the coagulation pathway is ________ |
Thrombin - factor II (Soluble protein) |
|
Describe the thrombotic process |
Tissue factor VII on diseased endothelium activates the factor Xa (part of prothrombinase complex) which converts prothrombin to thrombin
|
|
What is the direct role of thrombin? |
Convert fibrinogen to fibrin |
|
What are the secondary effects of thrombin? |
1) Promoting tissue factor production 2) Expression of adhesive molecules in endothelial cells 3) Smooth muscle cell proliferation 4) Leukocyte activation 5) Platelet aggregation |
|
Thrombin may also enhance _________ |
activity of protein S, thereby actually exerting an anti thrombotic effect |
|
Describe the process of Clot formation |
1) Endothelial damage
2) Activation of intrinsic pathway which involves fibrin growth and maintenance 3) ADP stimulates platelet aggregation 4) Tissue factor activates the extrinsic pathway which initiates fibrin formation 5) Common pathway activates Factor X |
|
What are the predisposing conditions for clot formation? |
1) Immobilization 2) Surgery & immediate post-op period 3) Trauma to lower limb 4) Pregnancy & Contraceptives 5) Heredity 6) CHF, MI, A Fib 7) Clotting factors deficiencies |
|
What are the indications for anticoagulant therapy? |
1) Pulmonary embolism 2) DVT 3) A Fib 4) Heart valve prosthesis 5) Acute MI 6) TIA/Stoke 7) Hip fracture - for prevention (temporarily) |
|
What are the characteristics of Heparin? |
Unfractionated 1) Mucopolysaccharides 2) Unfractionated (pig mucosa or bovine lung) 3) Low molecular weight 4) IV or SQ (NOT IM) |
|
What is the mechanism of action of Heparin? |
binds to Antithrombin III and inactivates factor Xa, XIa and XIIa |
|
Heparin dosing |
Loading dose (70 - 100 units/kg) is much higher than maintenance dose (18 units/kg) |
|
What is the adjustment of Heparin dose based on? |
aPTT 1) test done every 6 hours 2) always wait 6 hours before testing again after a change in dose |
|
What are the adverse effects of Heparin? |
1) Hemorrhage 2) Thrombocytopenia (HIP) 3) Paradoxical thrombosis |
|
What is Paradoxical thrombosis? |
Condition in which arterial or venous clots may develop after a period of heparin therapy - caused by production of antiplatelet antibodies that induce clotting |
|
What should be done in case of Heparin overdose? |
Should use 1) Protamine - a specific antidote 2) Whole blood transfusion 3) Fresh frozen plasma transfusion |
|
Name the Low molecular weight heparins |
1) Enoxaparin (Lovenox) 2) Dalteparin (Fragmin) 3) Ardeparin (Normiflo) 4) Tinzaparin (Innohep) |
|
Fondaparinux (Arixtra) is ____________ |
Synthetic pentasaccharide Leads to efficient inactivation of factor Xa 1) Heparinoid 2) Works the same way as haparin - however doesn't cause HIT Indication of use is VTE |
|
Low molecular weight heparin has less chances of _____ compared to heparin |
Less chances of HIT |
|
What are the indications of Low molecular weight heparin? |
1) DVT and PE treatment 2) May be used in out patient therapy as well |
|
What are the contraindication Heparin? |
1) Low renal function 2) Overweight or underweight |
|
What are the contraindication of Fondaparinux? |
if creatinine clearance < 30 mL/min
|
|
What are the types of Direct Thrombin inhibitors (DTI)? |
1) Divalent
2) Univalent |
|
Name the Divalent DTIs |
1) Hirudin 2) Lepirudin (Refludan) 3) Bivalirudin (Angiomax) |
|
What are the characteristics/MOA of Lepirudin (Refludan)? |
1) Derivative of Hirudin
2) Alternative to Heparin 3) Works in the presence of HIT 4) Less monitoring 5) IV preparation 6) Need to monitor PTT (less frequently) |
|
What are the adverse effects Lepirudin (Refludan)? |
1) Hemorrhage
2) Renal impairment??? |
|
What are the characteristics/MOA of Bivalirudin (Angiomax)? |
1) IV 2) Quick onset 3) Short half-life 4) Indication: Cath procedures |
|
Name the Univalent DTIs |
1) Argatroban 2) Dabigatran (Pradaxa) |
|
What is the mechanism of action of Argatroban? |
1) Small molecule thrombin inhibitor 2) Used in patients with HIP |
|
Dabigatran (Pradaxa) is _________ |
1) First PO DTI |
|
Dabigatran (Pradaxa) absorption is ________ |
1) Rapid absorption 2) Bioavailability: 3-7% - remains relatively static under fast and fed conditions |
|
How is Dabigatran distributed? |
1) Plasma concentration peaks within 1 hour - delayed 2 hours by food consumption 2) Half life elimination = 12-17 hours |
|
How is Dabigatran metabolized? |
1) Metabolized by microsomal carboxylesterases in the liver 2) Does not affect CYP activity |
|
How is Dabigatran excreted? |
1) Urine (7% as unchanged drug) 2) Feces (86% of total dose) |
|
What are the drug interactions of Dabigatran? |
1) P-glycoprotein inducer - Avoid taking it with Rifampin --- can make dabigatran less effective 2) Drug food interaction - Food has no effect on bioavailability - However delays the time to peak by 2 hours |
|
What are the adverse effects of Dabigatran? |
1) Dyspepsia 2) Fatigue 3) Dizziness 4) Dyspnea 5) Peripheral edema 7) Diarrhea 8) GI bleed 9) MI 10) Potential for accumulation in presence of renal dysfunction |
|
What are the monitoring parameters of Dabigatran? |
1) Monitor aPTT - value > 2.5x control may indicate over-anticoagulation 2) Ecarin clotting test (ECT) (if available) 3) Prothrombin time (PT) 4) CBC w/ diff 5) Bleeding |
|
What is the dosing for Dabigatran? |
1) 150mg PO BID 2) In case of renal impairment: - Cr Cl 15-30: 75mg PO BID - Cr Cl , 15: no recommendation 3) In case of hepatic impairment: - No adjustment required |
|
Dibigatran vs. Warfarin |
1) Patients w/ A Fib - dabigatran given at dose of 110mg BID (same effectiveness) - however, lower rates of major hemorrhage 2) Dabigatran administered at a dose of 150mg BID as compared with warfarin (superior effect) - lowers the rates of stroke and systemic embolism - however, similar rates of major hemorrhage |
|
Should dabigatran be used based on the trial? |
1) Same effectiveness with lower hemorrhage risks at 110mg BID 2) Superior effectiveness at lower risk for stroke or embolism at 150mg BID - w/ same hemorrhage risk 3) Wide therapeutic window - safety and efficacy depends on drug compliance 4) BID dose may increase non adherence to tx 5) No specific antidote yet 6) Renal/hepatic impairment 7) High risk of bleeding |
|
Name the Direct factor Xa inhibitors |
1) Rivaroxaban (Xarelto) 2) Apixaban (Eliquis) |
|
What are the characteristics of Rivaroxaban (Xarelto) (PO)? |
1) Predictable pharmacology 2) High bioavailability 3) Low risk of drug-drug interaction 4) Fixed dose 5) No requirements for monitoring 6) Similar efficacy as enoxaparin (Lovenox) 7) No diff in major bleeding btwn rivaroxaban and enoxaparin 8) Wide therapeutic window |
|
What is the mechanism of action of Rivaroxaban? |
1) Specific, competitive, direct Xa inhibitor 2) Inhibits free and clot-associated FXa activity and prothrombinase activity 3) Inhibits thrombin generation via inhibition of FXa activity - prolongs time to thrombin generation - inhibits peak thrombin generation - reduces the total amount of thrombin generated 4) Has a potent effect on aPTT & PT 5) Does not require a cofactor |
|
What are the indications for Rivaroxaban (Xarelto)? |
1) Treatment 2) Secondary Prevention of VTE |
|
What are the Vitamin K dependent factors? |
1) Factor VII 2) Factor IX 3) Factor X 4) Factor II |
|
What is the mechanism of action Vitamin K? |
1) Plays a major role in blood clotting 2) When given too much - reverses the effects of blood thinning medications such as (warfarin) |
|
What is the mechanism of action of Warfarin? |
1) Antagonizes Vitamin K 2) Depletes Vitamin K dependent factors (II, VIII, IX, X, protein C, protein S) 3) Onset of action 1-2 days 4) "True" anticoagulation in 2-7 days |
|
What are the characteristics of Warfarin? |
1) Well absorbed 2) Highly protein bound 3) Metabolized by the liver 4) Should always be monitored via INR (2-3) Therapeutic goal = 1:2 |
|
What are the Warfarin Dosing strategies? |
1) Do not load!
2) a Therapeutic PT does not mean "True" anticoagulation 3) Continue heparin therapy even along with warfarin until INR at therapeutic goal 4) Start one day after initiating heparin 5) Starting dose: 5mg-7.5mg / day |
|
What are the adverse effects of Warfarin? |
1) Bleeding 2) Thrombocytopenia |
|
What are the Drug-interactions of Warfarin? |
1) Enzyme inducers (antiepileptics) 2) Enzyme inhibitors (cimetidine, antibiotics) 3) Protein displacement (digoxin) |
|
What are Enzyme inducers? |
e.g. Antiepileptics 1) Enzyme inducer leads to fast metabolism and excretion of warfarin 2) Making it less effective 3) Causing more clotting |
|
What are Enzyme inhibitors? |
e.g. 1) Cimetidine 2) Antibiotics 1) Enzyme inhibitor will prevent the metabolism of warfarin 2) Leads to warfarin in circulation for longer duration - Increasing the effects of warfarin 3) Causing more bleeding |
|
Protein displacement |
e.g. Digoxin 1) Digoxin has higher protein affinity hence binds to the protein resulting in more free warfarin 2) Free warfarin (active) 3) Increasing the effects of warfarin 4) Causing more bleeding |
|
What are the signs of Warfarin Overdosage? |
Any unusual bleeding 1) Blood in stool or urine 2 )Excessive menstrual bleeding 3) Bruising 4) Excessive nose bleeds/ bleeding gums 5) Persistent oozing from superficial injuries 6) Bleeding from tumor ulcer or other lesions |
|
What are the Food-drug & other interactions of Warfarin? |
1) Vitamin K containing foods - Ok to continue the regular portion however important to inform the Dr. (how much) - Also important to inform the Dr. if any changes made in the intake (decreased or increased) 2) Antacids 3) Smoking |
|
What should be done in case of Warfarin - Bleeding? |
1) Fresh Frozen Plasma transfusion - Contains all the clotting factors 2) Start the patient on Vitamin K - If INR > 6 ***Higher INR = Over anticoagulation *** Important to control bleeding |
|
What is effective patient education? |
1) Teach basic concepts of safe, effective anticoagulation
2) Discus importance of regular INR monitoring 3) Counsel on use of other medications, alcohol 4) Develop creative strategies for improving compliance 5) Tell patients to take the warfarin right before dinner (for compliance) |
|
What are the Peri-Procedural management? |
1) Stop warfarin 5-7 days prior to procedure 2) Start enoxaprin at treatment dose (1mg/Kg SQ every 12 hours) 3) Last dose of enoxaparin 24 hours prior to procedure 4) Restart enoxaprin and warfarin (at previously stable dose) the evening following procedure 5) Continue until INR at therapeutic goal |
|
Name the Antiplatelet agents |
1) Ticlopidine (Ticlid) - Slow in producing anti platelet activity - Limited use 2) Clopidogrel (Plavix) - More active than ticlopidine - Better side effects profile 3) Prasugerel (Effient) - Similar to Clopidogrel 4) Ticagrelor (Brilinta) (IV) |
|
What is the mechanism of action of Antiplatelet agents? |
Inhibits ADP-dependent activation of GP IIb/IIIa complex |
|
What are the indications for Antiplatelet agents? |
1) ACS 2) Post strokes 3) Stroke Prevention |
|
What are the indications for Ticlopidicine (Ticlid)? |
1) Used when Aspirin is contraindicated 2) Use has been limited due to unacceptable side effect profile |
|
What are the benefits of using Clopidogrel (Plavix) compared to Ticlopidicine? |
1) 6 times more active compared to Ticlopidicine 2) Better side effect profile |
|
Ticlopidicine and Clopidogrel are used for prophylactic therapy in _______ |
High risk percutaneous coronary interventions |
|
Name the Antiplatelet agent monoclonal antibody |
Abciximab |
|
Name the Natural Antiplatelet agent |
Disintegrin family: RGD containing proteins ** from viper venom ** |
|
Name the Non peptide antiplatelet agents |
1) Tirofiban 2) Lamifiban 3) Fradafiban |
|
Name the Oral antiplatelet agents |
1) Xemilofiban 2) Orofiban 3) Lefradafiban 4) Sibrafiban 5) Roxifiban |
|
What are the Antiplatelet agents herbal interactions? |
Decreases platelet aggregation |
|
What is the mechanism of action of Thrombolytics? |
Thrombolytics are Proteins Dissolves the clot by 1) acting on plasminogen to form plasmin 2) plasmin cleaves fibrin |
|
What are the Indications for thrombolytics? |
MI patients - Remarkable improvements in outcomes - Must be started as soon as diagnosis is made |
|
Name the Thromobolytic medications |
1) Streptokinase (streptase) 2) Urokinase 3) Antistreplase (Eminase) 4) Alteplase (Activase, t-PA) 5) Reteplase (Retavase) 6) Tenecteplase (TNKase) |
|
Which are the Thrombolytics that needs to be started early? |
1) Alteplase (Activase, t-PA) 2) Reteplase (Retavase) 3) Tenecteplase (TNKase) |
|
Factor _____ with shortest half life on the intrinsic pathway of the clotting cascade |
Factor VII
|
|
LMWH |
Ending in "parin" |
|
Divalent DTIs |
Ending in "rudin" |
|
Direct factor Xa Factor |
Ending in "xaban" |
|
Non Peptide and Oral antiplatelet |
Ending in "fiban" |
|
Thrombolytic medications |
Ending in "ase" |
|
List the Anticoagulants that work againsT factor Xa |
1) Direct factor Xa inhibitors 2) DTI 3) Fondaparinux (Arixtra) 4) LMWH 5) Unfractionated Heparin 6) Warfarin (Vitamin K antagonist) |
|
Heparin indirectly inhibits __________ and LMWH indirectly inhibits __________ |
1) Factor IIa & Xa 2) Factor Xa more than Factor IIa |
|
Name the Synthetic peptide |
Eptifibatide |